west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "杨瑜瑾" 2 results
  • Expression of epidermal growth factor receptor in triple-negative breast cancer and its correlation with clinicopathologic features:a meta-analysis

    ObjectiveTo investigate the expression of epidermal growth factor receptor (EGFR) in triple-negative breast cancer (TNBC) and its relation with clinicopathologic features. MethodsA computer search of PubMed, Web of Science, CNKI, Wanfang Data, and VIP databases were conducted to select clinical studies on EGFR expression in the TNBC according to the inclusion and exclusion criteria, and the search period was from database establishment to January 2022. Two researchers independently screened the literature, extracted the data, and evaluated the quality of the literature before conducting meta-analysis using RevMan 5.4 software. ResultsA total of 28 studies including 7 956 patients were included. The results of meta-analysis showed that the positive rate of EGFR expression in the TNBC patients was higher than that in the non-TNBC patients [OR=5.16, 95%CI (4.04, 6.58), P<0.000 01], and the proportions of patients with axillary lymph node metastasis [OR=3.11, 95%CI (1.56, 6.19), P=0.001] and with tumor diameter >2 cm [OR=2.09, 95%CI (1.18, 3.72), P=0.01] in the patients with EGFR positive were higher than those the patients with EGFR negative, no correlation was found that the proportion of patients with histological WHO classification 3 between the patients with EGFR positive expression and EGFR negative expression (P=0.07). ConclusionFrom the results of this meta-analysis, EGFR expression might be associated with the occurrence, development, and metastasis of patients with TNBC.

    Release date: Export PDF Favorites Scan
  • 曲妥珠单抗生物类似药与原研曲妥珠单抗联合帕妥珠单抗治疗HER2阳性乳腺癌患者疗效与安全性的回顾性队列研究

    目的比较HER2阳性乳腺癌患者在新辅助治疗中原研曲妥珠单抗与生物类似药的病理完全缓解(pathologic complete response,pCR)率及不良事件发生率的差异。方法采用回顾性分析法,收集 2021年1月至2022年10月期间在西南医科大学附属医院乳腺外科完成TCbHP方案新辅助治疗及手术治疗的 117例人类表皮生长因子受体2(human epidermal growth factor receptor 2,HER2) 阳性乳腺癌患者的临床病理资料。疗效评价依据实体肿瘤疗效评价标准(RECIST)1.1和 Miller-Payne(MP)系统,采用不良事件通用术语标准5.0进行不良事件发生率统计。结果117例患者中达到总体病理完全缓解(total pathologic complete response,tpCR)者曲妥珠单抗生物类似药汉曲优(HLX02,Zercepac)组占比70.2% (33/47),原研曲妥珠单抗赫赛汀组占比72.9% (51/70),2组比较差异无统计学意义(P=0.755);达到乳腺病理完全缓解(breast pathologic complete response,bpCR)者汉曲优组占比76.6% (36/47),赫赛汀组占比74.3.9% (52/70),2组比较差异无统计学意义(P=0.777)。分子分型为HER2+HR+ (三阳性)组与HER2+HR–(HER2过表达)组患者的tpCR率比较差异有统计学意义(61.6%比88.6%,P=0.002),bpCR率比较差异也有统计学意义(67.1%比88.6%,P=0.009)。在HER2+HR+患者中汉曲优组与赫赛汀组的tpCR率比较差异无统计学意义(66.7%比57.5%,P=0.423),bpCR率比较差异也无统计学意义(75.8%比60.0%,P=0.154);在HER2+HR–患者中汉曲优组与赫赛汀组的的tpCR率比较差异无统计学意义(78.6%比93.3%,P=0.354),bpCR率比较差异也无统计学意义(78.6%比93.3%,P=0.354)。治疗后所有患者均出现了可控的不良事件, 2组患者在心脏、血液系统和肝肾功能方面的不良事件发生率以及 ≥3 级不良事件的发生率均相似,差异均无统计学意义(P>0.05)。结论赫赛汀与其生物类似药汉曲优在新辅助治疗中的疗效和安全性相似,这为 HER2 阳性乳腺癌患者提供了更多的治疗选择。

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content